Anginex is a designed peptide 33mer that functions as a cytokinelike agent to inhibit angiogenesis. Although this short linear peptide has been shown by NMR and CD to form a nascent β-sheet conformation in solution, the actual bioactive structure formed upon binding to its receptor on the surface of endothelial cells could be quite different. By using a series of double-cysteine disulphide-bridged analogues, we provide evidence in the present study that the β-sheet is in fact the bioactive conformation of anginex. CD and NMR spectral analysis of the analogues indicate formation of a β-sheet conformation. Three functional assays, endothelial cell proliferation, apoptosis and in vitro angiogenesis, were performed on all analogues. As long as the placement of disulphide bonds preserved the β-strand alignment, as in the proposed bioactive conformation, bioactivities were preserved. Knowledge of the bioactive conformation of anginex will aid in the design of smaller molecule mimetics of this potent antiangiogenic peptide.
INTRODUCTION
Angiogenesis, the formation of new blood vessels out of preexisting capillaries, is pivotal to a broad array of biological functions, ranging from normal processes like embryogenesis and wound healing to abnormal processes such as tumour growth, arthritis, restenosis and diabetic retinopathy [1, 2] . The use of agents that can inhibit angiogenesis in vitro and in vivo, particularly in anti-tumour research, has indicated that anti-angiogenic therapy can be a therapeutic modality in the future. Most anti-angiogenic agents have been discovered by identifying endogenous molecules, primarily proteins, which inhibit endothelial cell (EC) growth. This traditional approach has produced a number of anti-angiogenics, such as platelet factor-4 (PF4) [3] , thrombospondin-1 [4] , angiostatin [5] , endostatin [6] and bactericidal-permeability increasing (BPI) protein [7] .
Recently, we have reported [8, 9] the anti-angiogenic activity of a novel peptide 33mer (βpep-25 or anginex). Anginex belongs to a family of homologous βpep peptides that were designed by using basic folding principles and incorporating short sequences from the β-sheet domains of α-chemokines and BPI protein [10] . All βpep peptides form β-sheets to varying degrees and can selfassociate in solution as dimers and tetramers [9, 10] . A highresolution NMR structure of tetrameric βpep-4 demonstrated that its monomer subunits are folded into an amphipathic three-stranded anti-parallel β-sheet motif [11] . Two types of six-stranded anti-parallel β-sheet dimers can form and these dimers associate via their hydrophobic faces into tetramers. Although a high-resolution structure of anginex (βpep-25) could not be determined by using NMR because of aggregate exchange resonance broadening, CD and NMR studies [8, 9] indicate that Abbreviations used: BPI protein, bactericidal-permeability increasing protein; bFGF, basic fibroblast growth factor; CP, cyclicized peptide; EC, endothelial cell; HUVEC, human umbilical-vein EC; NOE, nuclear Overhauser effect; PF4, platelet factor-4; PFG, pulsed-field gradient; PI, propidium iodide; RMS, root mean square. 1 To whom correspondence should be addressed (e-mail mayox001@umn.edu).
anginex also folds primarily into tetrameric β-sheet sandwiches at millimolar concentrations. At concentrations in the micromolar range and lower, however, anginex exists in solution primarily in the monomer state and is composed of a relatively broad distribution of conformations with considerable random coil and some β-sheet character [12] . Therefore, at the micromolar concentrations used in in vitro bioassays and in vivo animal studies demonstrating the anti-angiogenic [8, 9] and anti-tumour [13] [14] [15] potency of the peptide, anginex is mostly a random coil monomer. Therefore the bioactive structure of anginex, which is selected from this rather broad conformational distribution, remains unclear. The aim of the present study was to test the hypothesis that the bioactive conformation of anginex (βpep-25) is a β-sheet with the same strand alignment as in the NMR-derived structure of homologous βpep-4 (see Figure 1 ) [11] . To accomplish this, a series of disulphide-linked peptide analogues of anginex were made. By comparing activities from all 30 members of the βpep library, it has already been deduced [9] that functionally key residues in anginex are primarily hydrophobic residues, i.e. Leu 5 , Val 7 , Ile 20 , Val 22 and Leu 24 . Because of this, cysteine residues replaced residues primarily at positions that would be on the hydrophilic face of the amphipathic anginex β-sheet. Moreover, to simplify peptide synthesis and purification, six functionally nonessential residues at the C-terminus of anginex [9] were removed, creating a peptide 27mer analogue of anginex that is shown in the present study to be equipotent with the parent peptide. Double-substituted cysteine pairs were made: Cys 6 
EXPERIMENTAL

Peptide preparation
Peptides were synthesized using fluoren-9-ylmethoxycarbonyl ('Fmoc') chemistry on a Milligen/Biosearch 9600 peptide solidphase synthesizer, as described previously [8, 9] . To form intramolecular disulphide bonds, crude peptides were solubilized at low concentrations (100 µM) and cysteine residues were oxidized by slowly bubbling wet oxygen gas into a stirred aqueous solution overnight at room temperature. Freeze-dried crude peptides (oxidized) were purified by preparative reversephase HPLC on a C18 column with an elution gradient of 0-60 % (v/v) acetonitrile with 0.1 % (v/v) trifluoroacetic acid in water. Purity and composition of the peptides were verified by HPLC (Beckman Model 6300), amino acid analysis and MS. The presence of the disulphide bond was checked in all peptides by using 5,5 -dithiobis-(2-nitrobenzoic acid (Ellman's reagent; 'DTNB') pre-and post-treatment with dithiothreitol.
CD
Aqueous solutions for CD were prepared by dissolving the freeze-dried peptide in the appropriate amount of water to give final peptide concentrations of 0.1 mM at pH 5.5. Concentrations were verified by tryptophan absorption at 280 nm. CD spectra were recorded on a Jasco J-710 spectrophotometer using either a 0.01 cm or 0.1 cm path-length thermally jacketed quartz cuvette maintained at 24 or 37
• C with a NesLab water bath. Acquisition was performed using a 50 nm/min scan rate, 1 nm bandwidth and 2 s response. The appropriate baseline was subtracted from each spectrum. Reported spectra are averages of six scans and are expressed as mean residue ellipticity. CD basis spectra (α-helix, β-sheet and random coil) were measured with poly(lysine) and poly(glutamic acid) (Sigma) using conditions and parameters reported previously [16, 17] . Experimental CD spectra were fitted with a linear combination of α-helix, β-sheet and random coil basis spectra to estimate secondary structure contributions.
NMR measurements
For NMR measurements, the freeze-dried peptide was dissolved in water at a concentration of approx. 2 mM. The pH was adjusted to pH 5.5 by adding microlitre quantities of NaOH or HCl to the peptide sample. NMR spectra were acquired on a Varian UNITY Plus-600 NMR spectrometer using a homonuclear approach described previously [8] . Data were processed directly on the spectrometer or offline using VNMR (Varian, Inc., Palo Alto, CA, U.S.A.) or NMRPipe [18] on an SGI workstation and were analysed using Sparky (T. D. Goddard and D. G. Kneller, SPARKY 3, University of California, San Francisco, CA, U.S.A.).
Since cyclicized peptides (CPs) are relatively hydrophobic and amphipathic, pulsed-field gradient (PFG)-NMR self-diffusion measurements were performed as a check for peptide aggregation. PFG-NMR experiments were performed and analysed as described by Mayo et al. [10] using a Varian Unity-Plus 500 NMR spectrometer. The maximum magnitude of the gradient was 60 G/cm, and the PFG longitudinal eddy-current delay pulse sequence was used for all self-diffusion measurements which were performed in 2 H 2 O at temperatures of 5 • C and 40
• C. Peptide concentrations ranged from 0.1-2 mM.
Structural modelling
Analysis of nuclear Overhauser effect (NOE) data and structural modelling (using X-PLOR [19] ) were performed essentially as described previously [20] . Calculated structures were superimposed using the SwissPdbViewer [21] or Insight II (Accelrys, Inc., San Diego, CA, U.S.A.) and were analysed using X-PLOR analysis routines.
Human umbilical-vein EC (HUVEC) cultures
HUVECs were harvested from normal human umbilical cords by perfusion with 0.125 % (w/v) trypsin/EDTA. Harvested HUVECs were cultured in gelatin-coated tissue-culture flasks and subcultured 1:3 once a week in culture medium [RPMI-1640 with 20 % (v/v) human serum supplemented with 2 mM glutamine, 100 units/ml penicillin and 0.1 mg/ml streptomycin].
Proliferation measurement
EC proliferation was measured using a [
3 H]thymidine incorporation assay. HUVECs were seeded at 5000 cells/well in flat-bottomed tissue-culture plates and grown for 3 days in culture medium in the absence or presence of regulators. During the last 6 h of the assay, the culture was pulsed with 0.5 µCi of [methyl-3 H]thymidine/well. Results are expressed as the arithmetic mean c.p.m. of triplicate cultures.
Apoptosis measurement
HUVECs were cultured in fibronectin-coated tissue-culture flasks in culture medium [22] . Apoptosis was measured by determination of subdiploid cells after DNA extraction and subsequent staining with propidium iodide (PI) as described previously [23] . Briefly, HUVECs were cultured for 3 days in the presence of 10 ng/ml basic fibroblast growth factor (bFGF) and the conditions as mentioned above. Serum deprivation of HUVECs was used as a positive control for apoptosis. Cells were then harvested and subsequently fixed and permeabilized in 70 % (v/v) ethanol at − 20
• C. After at least 2 h, the cells were centrifuged and resuspended in DNA extraction buffer [45 mM Na 2 HPO 4 , 2.5 mM citric acid and 0.1 % Triton X-100 (pH 7.4)] for 20 min. PI was added to a final concentration of 20 mg/ml and red log-scale fluorescence was analysed on a FACS-calibur. Apoptosis was quantified as the percentage of cells with PI fluorescence below the fluorescence of cells in the G 0 /G 1 (diploid) phase of the cell cycle. Cells with PI fluorescence less than 10 % of cells in G 0 /G 1 phase were regarded as cells in the advanced stages of cell death.
In vitro angiogenesis assay
Sprouting and tube formation of bovine ECs were studied using Cytodex-3 beads overgrown with bovine ECs in a three-dimensional collagen gel (vitrogen-100; Collagen Corp., Fremont, CA, U.S.A.) as described by van der Schaft et al. [24] . Following gelation, culture medium containing 20 ng/ml bFGF, with or without anginex or CP analogues, was applied on top of the gel. Photographs were taken after 24 h of cell culture at 37
• C. Sprouts were traced on transparent paper and digitized by scanning using HPscan software. Analysis of the amount of sprouting was performed by binarization of the file and quantification of sprout pixel count using Scion Image software, which yields a measure of sprout length [25] .
RESULTS AND DISCUSSION
For the CP series, all CP analogues have the same sequence as anginex minus the six C-terminal residues Arg-Glu-Leu-SerLeu-Asp (Figure 1 ). CP-1 is the control linear peptide 27mer (no cysteine residues), and CP-2 to CP-8 are double-cysteinesubstituted disulphide-bridged peptides: Cys 6 Figure 1 , and positions for disulphide bonds in CP-2 to CP-6 are indicated by curved lines at the right of the CP-1 sequence. Because functionally key residues in anginex are primarily hydrophobic, i.e. Leu 5 , Val 7 , Ile 20 , Val 22 and Leu 24 , and would lie on one side of the amphipathic structure in a β-sheet conformation [9] , residues on the hydrophilic face (and not the hydrophobic face) of the proposed β-sheet were substituted with cysteine residues. For assurance that cysteine-substituted positions did not affect activity of the parent peptide, single-substituted alanine variants (Ser 6 → Ala, Gln 
CD
CD and NMR spectroscopies were used to assess the conformation of CP analogues. For all CP analogues, far-UV CD traces indicated a mixture of β-sheet and random coil conformations (Figure 2) , with the degree of β-sheet character corresponding to the intensity of the characteristic 217 nm trough [17, 26, 27] . Linear combinations of secondary structure basis spectra (α-helix, β-sheet and random coil) fitted to the CP analogue spectra (Figure 2, inset) showed the largest β-sheet content (79 %) in the linear CP-1 peptide and the smallest (40 %) in CP-6. Fitted data indicate the absence of helical content for most of the CP analogues. Even though CP-4, CP-5 and CP-6 show 2-6 % helix content, this contribution is small enough that it is within the error from the fitting process. In addition, because the CP analogues are relatively flexible, the secondary structure contributions are only meant to semi-quantify the trend in β-sheet content. Nevertheless, the CP analogue conformational distributions are consistent with that for anginex [11] .
H NMR conformational analysis
Even though CD data demonstrate the presence of significant populations of β-sheets in all CP analogues, proton NMR spectra for all CP analogues, except CP-2, are characteristic of mostly random coil conformations (results not shown). CP-2 is the only CP analogue that shows well-dispersed resonances indicative of a well-folded structure [28, 29] . Since the parent anginex peptide exists in solution in a monomer/dimer/tetramer equilibrium [29, 30] , PFG-NMR self-diffusion measurements were performed on CP analogues (results not shown). Analysis of the CP analogue diffusivities indicates that, at a concentration of 2 mM, CP-2 is mostly dimeric, whereas the other CP analogues are a mixture of dimers and monomers. None of the CP analogues apparently associates with the tetramer state like anginex.
NMR structure of CP-2
Because initial NMR experiments indicated that CP-2 is wellfolded, a complete NMR structure analysis of this peptide was performed. The αH-NH region of a TOCSY plot of CP-2 shows high frequency dispersion of NH and αH resonances, indicating the presence of a well-folded β-sheet conformation ( Figure 3A) . This is also evident by the observation of cross-strand αH-αH NOEs ( Figure 3B and Figure 4A ). Structurally, these NOESY data indicate the presence of the same anti-parallel β-sheet strand alignment as observed in βpep-4 and other βpep peptides [11] .
For CP-2, conformational modelling was performed using NOE data acquired for the peptide. A total of 160 NOE distance constraints were derived from analysis of NOESY spectra. These include 94 intra-residue, 22 sequential, 16 medium-range (|i − j| < 5) and 28 long-range (|i − j| > 5) constraints. In addition, a total of eight hydrogen bonds were identified by inspection of initial CP-2 structures and from long-lived backbone NHs, giving rise to 16 hydrogen bond distance constraints. The total number of experimentally derived constraints was therefore 168, giving an average of six constraints/residue. Initially, 100 structures for CP-2 were calculated as described in the Experimental section. The best-fit superpositions of backbone Cα atoms for the final 18 structures are shown in Figure 4 (B). These structures showed no NOE violations greater than 0.5 Å (where 1 Å = 0.1 nm). Structural statistics (Table 1) show that the Nterminus is somewhat less structurally defined and that the †The final value of the NOE (E NOE ) was calculated with a force constant of 210 kJ · mol
structures satisfy experimental constraints quite well. In addition, and ψ angular order parameters are all > 0.8. Taken together, the above data indicate that the structures used to represent the solution conformation of CP-2 are well converged. The root mean square (RMS) deviation for backbone atoms of β-sheet residues (A) Key cross-strand NOEs and the overall fold for CP-2. Single-letter amino-acid notation is used. The best-fit superpositions of backbone Cα atoms for the final 18 structures are shown in (B). The RMS deviation for backbone atoms of β-sheet residues 6-12 and 19-25 (excluding terminal and loop residues) is 0.61 Å, and for backbone atoms of residues 6-25 (excluding N-and C-terminal residues) it is 1.13 Å.
6-12 and 19-25 (excluding terminal and loop residues) is 0.61 Å and for backbone atoms of residues 6-25 (excluding N-and Cterminal residues) is 1.13 Å.
Even though only CP-2 is well-folded as an anti-parallel β-sheet, it is most probable that peptides CP-3, CP-4, CP-5 and CP-6 share the same overall β-sheet fold, because they only differ in the position of the disulphide bridge.
CP analogues inhibit EC proliferation
CP analogues were tested for their ability to inhibit the proliferation of growth-factor-induced (bFGF, 10 ng/ml) HUVECs in the [ 3 H]thymidine incorporation assay [15] . Relative to the activity of the parent peptide anginex [8] , CP analogues effectively inhibited the proliferation of HUVECs to various extents ( Figure 5 ). Although the linear control, CP-1, and three of the disulphide-bridged variants, CP-4, CP-5 and CP-6, were essentially as effective as anginex, CP-2 and CP-3 appeared to be almost as active, and control peptides CP-7 and CP-8 were only slightly active. The kinetics of these anti-proliferative effects on ECs were similar to those found for anginex, with half-maximal effects after 36-40 h and maximal responses after 3 days. As with anginex, the inhibition of proliferation by CP analogues was specific for ECs, since proliferation of fibroblasts obtained from human endometrium was unaffected (results not shown).
CP analogues promote apoptosis in ECs
To investigate whether CP-induced inhibition of EC growth is based on specific induction of apoptosis in these cells, as was demonstrated for anginex [8] , HUVECs were exposed to 25 µM peptide for 48 h, and the percentage of cells undergoing apoptosis was quantified by analysis of DNA fragmentation following DNA extraction, PI staining and flow cytometric analysis. Although all CP analogues demonstrated apoptotic activity, CP-4 and CP-5 were the most active and even slightly more effective, on average, than anginex ( Figure 6A ). Since apoptosis in this assay is defined as those subdiploid cells with a minimum of 10 % of the DNA content of the diploid cells, advanced or late stage apoptosis may result in less than 10% of that value. Consequently, the total number of dead cells was also quantified ( Figure 6B ). The loss of ECs in G 2 and M (4n DNA) phases of the cell cycle is approx. 10 % or less (results not shown). The correlation between apoptosis induction and anti-proliferative effects suggests that CP analogues, like anginex, regulate EC growth by forcing ECs to undergo apoptosis.
In vitro angiogenesis assay
Since angiogenesis is a complex process, which, aside from EC proliferation, depends on cell migration and differentiation, the effects of CP analogues on angiogenesis were investigated in an in vitro collagen matrix-based sprout formation assay [13] [14] [15] . Figures 7(A-D) show raw data from this angiogenesis assay, and Figure 7 (E) gives the percentage of sprouting relative to control, as detailed in the Figure legend and the Experimental section. Although all CP analogues were able to inhibit sprout formation to various extents, the best responses, comparable with those from anginex, were observed with CP-1 and CP-2. It was somewhat surprising that CP-4, CP-5 and CP-6, which were the most effective at inhibiting EC proliferation, were not as effective in this assay. One reason for this could be the complexity of the collagen gel sprouting assay itself. Because these peptides must first navigate through the gel before exerting their effect on ECs, it may be that CP-1 and CP-2 permeate the gel better than other CP analogues or interact somewhat differently with the gel matrix. Alternatively, it may be that the sprouting assay is indeed the more sensitive indicator of anti-angiogenic potential. In any event, bioactivity in this angiogenesis assay decreased most when the β-strand alignment was shifted, as in CP-7 and CP-8, indicating that that specific strand alignment is crucial to maintaining full bioactivity.
Conclusions
In the present study, we demonstrate that the bioactive conformation of the anti-angiogenic anginex peptide is an antiparallel β-sheet. This finding is consistent with earlier results [8, 9] on anginex that in the β-sheet conformation all five hydrophobic residues (Leu 5 , Va l7 , Ile 20 , Val 22 and Leu 24 ), which were identified as being crucial to anti-proliferative activity, are proximal and are conformed on the hydrophobic face of the amphipathic β-sheet [9] . Comparison of the three-dimensional structures of several anti-angiogenic proteins, e.g. endostatin [31] , PF4 [32] , tumour necrosis factor [33] and BPI protein [34] , provides a higher level of structural commonality among anti-angiogenic proteins in that they are comprised primarily of anti-parallel β-sheet structure. Furthermore, a survey of amino acid sequences from numerous anti-angiogenic proteins reveals that they are compositionally similar, containing numerous hydrophobic and cationic residues. These structural and compositional characteristics, which appear to be functionally important, are embodied in anginex [9] . As structure-function relationships in these and other antiangiogenic proteins and peptides become known, it will be interesting to see if this is a common feature among antiangiogenic proteins. Knowing that this β-sheet conformation is that which promotes anti-angiogenic activity will aid in the development of small molecule mimetics of the anginex peptide.
